In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in CHF23.7mm for NovaShunt AG

Executive Summary

NovaShunt AG (implantable pumps for fluid management) has raised CHF23.7mm ($25.6mm) in a Series B financing of preferred stock. BioMedInvest AG, Entrepreneurs Fund, and Capricorn Health-tech Fund co-led the round (and each add a board member) and were joined by returning investors NeoMed (NovaShunt’s largest shareholder) and VI Partners.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies